Compare MYI & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MYI | CMPS |
|---|---|---|
| Founded | N/A | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 747.8M | 778.7M |
| IPO Year | 1994 | 2020 |
| Metric | MYI | CMPS |
|---|---|---|
| Price | $10.92 | $6.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $27.14 |
| AVG Volume (30 Days) | 169.6K | ★ 4.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.98 | $2.25 |
| 52 Week High | $11.46 | $8.90 |
| Indicator | MYI | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 30.01 | 45.95 |
| Support Level | $10.88 | $5.95 |
| Resistance Level | $11.14 | $7.02 |
| Average True Range (ATR) | 0.08 | 0.49 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 1.28 | 12.42 |
BLACKROCK MUNIYIELD QUALITY FUND III, INC. is an investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes, as is consistent with its investment policies and prudent investment management. The fund invests a majority of its assets in municipal obligations exempt from U.S. federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax). Under normal market conditions, the fund invests mainly in long-term municipal obligations that are investment-grade quality or are considered by the adviser to be of comparable quality at the time of investment. It can also invest directly in such securities or synthetically through the use of derivatives.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.